Literature DB >> 31490000

Extended thromboprophylaxis following colorectal surgery in patients with inflammatory bowel disease: a comprehensive systematic clinical review.

T McKechnie1, J Wang1, J E Springer2, P L Gross1,3, S Forbes1,2, C Eskicioglu1,2.   

Abstract

AIM: Patients with inflammatory bowel disease (IBD) are at increased risk of postoperative venous thromboembolism (VTE) following major abdominal surgery. The pathogenesis is multifactorial and not fully understood. A combination of pathophysiology, patient and surgical risk factors increase the risk of postoperative VTE in these patients. Despite being at increased risk, IBD patients are not regularly prescribed extended pharmacological thromboprophylaxis following colorectal surgery. Currently, there is a paucity of evidence-based guidelines. Thus, the aim of this review is to evaluate the role of extended pharmacological thromboprophylaxis in IBD patients undergoing colorectal surgery.
METHOD: A search of Ovid Medline, EMBASE and PubMed databases was performed. A qualitative analysis was performed using 10 clinical questions developed by colorectal surgeons and a thrombosis haematologist. The Newcastle-Ottawa Scale was utilized to assess the quality of evidence.
RESULTS: A total of 1229 studies were identified, 38 of which met the final inclusion criteria (37 retrospective, one case-control). Rates of postoperative VTE ranged between 0.6% and 8.9%. Patient-specific risk factors for postoperative VTE included ulcerative colitis, increased age and obesity. Surgery-specific risk factors for postoperative VTE included open surgery, emergent surgery and ileostomy creation. Patients with IBD were more frequently at increased risk in the included studies for postoperative VTE than patients with colorectal cancer. The risk of bias assessment demonstrated low risk of bias in patient selection and comparability, with variable risk of bias in reported outcomes.
CONCLUSION: There is a lack of evidence regarding the use of extended pharmacological thromboprophylaxis in patients with IBD following colorectal surgery. As these patients are at heightened risk of postoperative VTE, future study and consideration of the use of extended pharmacological thromboprophylaxis is warranted. Colorectal Disease
© 2019 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  colorectal surgery; inflammatory bowel disease; pharmacological thromboprophylaxis; venous thromboembolism

Mesh:

Substances:

Year:  2019        PMID: 31490000     DOI: 10.1111/codi.14853

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

Review 1.  Cerebral Venous Sinus Thrombosis in Inflammatory Bowel Disease: A Review of Published Case Reports.

Authors:  Aishah Ibrahim Albakr; Noor AlMohish
Journal:  Perm J       Date:  2021-06-02

2.  Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  Xin-Yue Zhang; Hai-Cheng Dong; Wen-Fei Wang; Yao Zhang
Journal:  World J Gastroenterol       Date:  2022-04-28       Impact factor: 5.374

Review 3.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Kimberly Cheng; Adam S Faye
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

4.  The Duration and Magnitude of Postdischarge Venous Thromboembolism Following Colectomy.

Authors:  Christopher A Lewis-Lloyd; David J Humes; Joe West; Oliver Peacock; Colin J Crooks
Journal:  Ann Surg       Date:  2022-07-19       Impact factor: 13.787

5.  A postdischarge venous thromboembolism risk calculator for inflammatory bowel disease surgery.

Authors:  Cary Jo R Schlick; Tarik K Yuce; Anthony D Yang; Michael F McGee; David J Bentrem; Karl Y Bilimoria; Ryan P Merkow
Journal:  Surgery       Date:  2020-10-17       Impact factor: 3.982

6.  Association Between Missed Doses of Chemoprophylaxis and VTE Incidence in a Statewide Colectomy Cohort.

Authors:  Rhami Khorfan; Lindsey Kreutzer; Remi Love; Cary Jo R Schlick; Matthew Chia; Karl Y Bilimoria; Anthony D Yang
Journal:  Ann Surg       Date:  2021-04-01       Impact factor: 13.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.